AstraZeneca Merck & Co.\'s Lynparza hits main goal in Phase III study for pancreatic cancer httpswww.firstwordpharma.comnode1626831Â $AZN $MRK

AstraZeneca, Merck & Co.'s Lynparza hits main goal in Phase III study for pancreatic cancer https://www.firstwordpharma.com/node/1626831  $AZN $MRK

04:27 EST 26 Feb 2019 | FirstWord Pharma

AstraZeneca, Merck & Co.'s Lynparza hits main goal in Phase III study for pancreatic cancer https://www.firstwordpharma.com/node/1626831  $AZN $MRK

More From BioPortfolio on "AstraZeneca, Merck & Co.'s Lynparza hits main goal in Phase III study for pancreatic cancer https://www.firstwordpharma.com/node/1626831  $AZN $MRK"